There's no question biomarkers play a critical role in the drug development process, both in the clinical trial design and positioning a medicine in the marketplace. In most therapeutic areas, however, the science behind biomarkers is still at a nascent stage. The one exception? Oncology, where well validated markers have played--and continue to play--a key role in the success of important therapeutics such as Herceptin, Erbitux, and Vectibix. In this webinar, we'll hear from experts about the importance of biomarkers in the development of AstraZeneca's Iressa and Amgen's Vectibix, as well as from other stakeholders about what our evolving knowledge of oncology biomarkers means for the cancer medicines of tomorrow.
Featuring:
Ruth March
Personalized Healthcare Director
AstraZeneca
David Chang, M.D., Ph.D.,
Vice President, Global Development
Amgen
Ben Bonifant
Vice President, Business Development Practice
Campbell Alliance
Spiro Rombotis
President & CEO
Cyclacel Pharmaceuticals
Moderated by:
Roger Longman
Managing Director, Pharma
Windhover Information
Ellen Licking
Executive Editor
Windhover Information
__________________________________________________________________
